Sentences with phrase «immunotherapy center»

The Vaccine & Immunotherapy Center focuses the Institute's strengths in immunology, virology and immune - oncology disciplines to improve public health around the globe through the creation of new and improved interventions and treatments for some of the most dangerous and widespread diseases.

Hildegund C.J. Ertl, M.D. Caspar Wistar Professor in Vaccine Research Professor, Vaccine & Immunotherapy Center

Executive Vice President Director, Vaccine & Immunotherapy Center W.W. Smith Charitable Trust Professor in Cancer Research

The Vaccine & Immunotherapy Center brings together many outstanding researchers within the Institute to focus on new immune based approaches to induce protective tumor immunity, to control the tumor microenvironment, and to use humoral and cellular immunity to control or eliminate cancer.

The Wistar Institute was awarded a $ 1,494,972 grant by the Bill & Melinda Gates Foundation to advance a DNA - based vaccine candidate for protection against malarial infection utilizing a synthetic DNA platform created in the lab of David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer Research.

Executive Vice President Director, Vaccine & Immunotherapy Center W.W. Smith Charitable Trust Professor in Cancer Research Professor, Immunology, Microenvironment & Metastasis Program

Vice President, Scientific Operations Herbert Kean, M.D., Family Endowed Chair Professor Director, HIV - 1 Immunopathogenesis Laboratory Professor, Translational Tumor Immunology Program Professor, Vaccine & Immunotherapy Center Associate Director for Shared Facilities, Wistar Cancer Center

«Some approaches to creating cancer vaccines begin by extracting a patient's own immune cells, priming them with tumor antigens and returning them to the patient, a process that is complex and expensive,» says Mark Poznansky, MD, PhD, director of the MGH Vaccine and Immunotherapy Center and senior author of the report.

Professor, Vaccine & Immunotherapy Center Scientific Director, Animal Facility

Weiner joined The Wistar Institute as the Executive Vice President, Director of the Vaccine & Immunotherapy Center, and W.W. Smith Charitable Trust Professor in Cancer Research in 2016.

«Our work sheds light on the nature of CD32 as a molecule associated with transcriptionally active HIV and proves that targeting CD32 - positive cells is unlikely to hit the HIV latent reservoir,» said Mohamed Abdel - Mohsen, Ph.D., assistant professor in The Wistar Institute Vaccine & Immunotherapy Center and first author of the study.

«Identifying specific biomarkers of latently infected cells is considered as the «holy grail» in the HIV eradication field,» said lead corresponding author Luis J. Montaner, D.V.M., D.Phil., director of the HIV - 1 Immunopathogenesis Unit at The Wistar Institute Vaccine & Immunotherapy Center.

As a member of the Vaccine & Immunotherapy Center he studied accelerated vaccine development and targeted cancer therapies until February 2015.

David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center, and the W.W. Smith Endowed Chair in Cancer Research at The Wistar Institute, and peers received the 2018 Top Ten Clinical Research Achievement Award last night at the National Press Club in Washington, D.C.

In their report published in Cancer Immunology Research, a team from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH) describes how adding AMD3100 (plerixafor)-- previously approved for the stimulation of stem cell production prior to bone marrow transplantation — to their investigational drug VIC - 008 more than doubled the animals» survival time.

«This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production of antibodies of major relevance to human cancer,» said David B. Weiner, Ph.D., executive vice president of The Wistar Institute, director of The Wistar Institute Vaccine & Immunotherapy Center, W.W. Smith Charitable Trust Professor in Cancer Research, and senior author of the study.

Not exact matches

With a critical mass of 450,000 patients annually among them, the six centers have agreed to combine their efforts on planning clinical trials in immunotherapy, recruit patients quickly, and share the information learned — which could be the single biggest factor in speeding up drug development.

And when Ziskin's breast cancer had reemerged with brutal efficiency after a long remission, Parker had managed to get her into a last - ditch immunotherapy protocol at the Hutch, the famed Fred Hutchinson Cancer Research Center in Seattle — chartering private planes at his own expense to shepherd her back and forth from Los Angeles.

Immunotherapy research pioneers Carl June (left), Jedd Wolchok (center), and Jim Allison are among those partnering with PICI.

But an announcement on the website of Shenzhen's Dapeng New District, where the center is located, makes one mention of cancer cell immunotherapy, while identifying «precision medicine» as a main focus.

Judith Gasson, senior associate dean for research at the David Geffen School of Medicine at UCLA and director of the Jonsson Cancer Center, said researchers have long hoped to develop an effective and lasting immunotherapy to fight cancer.

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

«It will be much more powerful than the antibodies,» says Timothy Chan, who does clinical research in immunotherapy at Memorial Sloan Kettering Cancer Center in New York City.

For example, immunotherapies used to eradicate any remaining cancer could be started much sooner under this regimen, says Christopher Kanakry, M.D, a Kimmel Cancer Center researcher and co-first author of the study.

Allison, chair of the immunology department at the University of Texas M.D. Anderson Cancer Center in Houston and executive director of its research center on immunotherapy, spoke with Scientific American about the future prospects and limitations of immunothCenter in Houston and executive director of its research center on immunotherapy, spoke with Scientific American about the future prospects and limitations of immunothcenter on immunotherapy, spoke with Scientific American about the future prospects and limitations of immunotherapy.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

The overlap and density of these lymphocytes within the tumor and peripheral blood offer novel prognostic biomarkers for this deadly disease,» adds Richard Koya, MD, PhD, Associate Director of the Roswell Park Center for Immunotherapy and Director of the Institute's Vector Development and Production Facility.

Soon afterward, Allison returned to MD Anderson, lured by the opportunity to launch the center's $ 30 million Moon Shots immunotherapy research program.

In his day job, at the University of Texas MD Anderson Cancer Center in Houston, Allison serves as chair of the immunology department, deputy director of the David H. Koch Center for Applied Research of Genitourinary Cancers and executive director of the immunotherapy division of the Moon Shots Program, a multidisciplinary effort tackling cancer mortality.

«Jim's work has really allowed immunotherapy to become a game changer for patients with cancer,» says Elizabeth Jaffee, deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg ~ Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood - brain barrier.

The immunotherapy drug pembrolizumab — already FDA - approved for other forms of cancer - has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer Center.

«It appears that pregnant women infected with Zika can pass the virus to babies in utero and that newborns also may be susceptible to infection,» said Diamond, also an associate director of the university's Center for Human Immunology and Immunotherapy Programs.

Fecal transplants are already being used to treat stubborn colon infections of Clostridium difficile bacteria, notes immunotherapy researcher Alexandra Snyder of Memorial Sloan Kettering Cancer Center in New York City.

In 2012 she became the scientific director of the Immunotherapy Platform for The University of Texas MD Anderson Cancer Center.

His additional appointments include: head of the Swim Across America / Ludwig Collaborative Laboratory; associate director of the Ludwig Center for Cancer Immunotherapy; and director of the Parker Institute for Cancer Immunotherapy at MSK.

Following a postdoctoral fellowship at Memorial Sloan - Kettering Cancer Center (MSKCC) in New York, he joined the Ludwig Institute for Cancer Research at MSKCC, where he eventually became an associate member and was named director of Immunological Monitoring at the Ludwig Center for Cancer Immunotherapy.

The results of the study were published this week in the journal Nature Medicine from researchers at Penn's Abramson Cancer Center, including senior author Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the ACC, the University of Maryland School of Medicine, and Adaptimmune Therapeutics plc (Adaptimmune).

The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center report at the 2017 annual meeting of the American Society of Clinical Oncology.

These are exactly the research areas on which we are currently focusing at the Research Center for Immunotherapy,» emphasized Professor Hansjörg Schild, head of the research center at Mainz UniveCenter for Immunotherapy,» emphasized Professor Hansjörg Schild, head of the research center at Mainz Univecenter at Mainz University.

«Natural killer cells are very attractive targets for immunotherapy because they are able to kill tumor cells,» said Si - Yi Chen, M.D., Ph.D., a faculty member of the USC Norris Comprehensive Cancer Center and senior author of the study.

What's exciting is that half of those have responses that last for many years,» says Drew Pardoll, director of Bloomberg ~ Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins School of Medicine.

Maus - a former Penn faculty member who is now the Director of Cellular Immunotherapy at the Massachusetts General Hospital Cancer Center and an assistant professor of Medicine at Harvard Medical School - is the senior author on the study.

«This new class of immunotherapy drug traps white blood cells in the lymph nodes to prevent their escape into the gut where they cause inflammation,» said William J. Sandborn, MD, professor of medicine at UC San Diego School of Medicine and director of the Inflammatory Bowel Disease Center at UC San Diego Health.

The research team is led by Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the Abramson Cancer Center, along with David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson Cancer Center.

On 29 September, AAAS hosted a lively online discussion on Reddit's «Ask Me Anything» (AMA) forum on implicit bias in science — a discussion Smith joined, along with Shirley Malcom, AAAS» director of Education and Human Resources programs, Caleph B. Wilson, a biomedical scientist with Cellectis, a biopharmaceutical company, and Avery Posey, Jr., an instructor in the Center for Cellular Immunotherapies at the Perelman School of Medicine at the University of Pennsylvania.

In an accompanying editorial, Stanley Jordan, MD (Cedars - Sinai Medical Center) noted that if the findings are supported by additional studies, they could be of great help in counseling patients and possibly avoiding costly immunotherapy to reduce what appear to be largely benign donor - specific HLA antibodies.

Melanoma patients» response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies and enemies found in the digestive tract, researchers at The University of Texas MD Anderson Cancer Center report at the ASCO - Society for Immunotherapy in Cancer meetinimmunotherapy is associated with the diversity and makeup of trillions of potential allies and enemies found in the digestive tract, researchers at The University of Texas MD Anderson Cancer Center report at the ASCO - Society for Immunotherapy in Cancer meetinImmunotherapy in Cancer meeting in Orlando.

The second report, identifies the immunotherapy resistance mechanism in melanoma cells, is from a group led by Kai Wucherpfennig, MD, PhD, director of Dana - Farber's Center for Cancer Immunotherapy Research, and Shirley Liu, PhD, of Dimmunotherapy resistance mechanism in melanoma cells, is from a group led by Kai Wucherpfennig, MD, PhD, director of Dana - Farber's Center for Cancer Immunotherapy Research, and Shirley Liu, PhD, of DImmunotherapy Research, and Shirley Liu, PhD, of Dana - Farber.

«Our phase 1 trial combines gemcitabine with two novel cancer immunotherapies — a regimen that has not been tried before,» said Venepalli, a member of the UI Cancer Center.